Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Vachhani P, et al. Among authors: mesa r. Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38380373 Free PMC article. Review.
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Verstovsek S, et al. Among authors: mesa ra. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028. N Engl J Med. 2010. PMID: 20843246 Free PMC article. Clinical Trial.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Barbui T, et al. Among authors: mesa r. J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205761 Free PMC article.
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R. Gowin K, et al. Among authors: mesa r. Haematologica. 2012 Oct;97(10):1570-3. doi: 10.3324/haematol.2011.061390. Epub 2012 Mar 14. Haematologica. 2012. PMID: 22419578 Free PMC article.
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. Among authors: mesa ra. Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11. Br J Haematol. 2013. PMID: 23480528 Free PMC article. Clinical Trial.
541 results